References
- Al-Jaghbeer MJ, Justo JA, Owens W, et al. Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study. Infection. 2018;46:487–494.
- World Health Organization. Global Action Plan on antimicrobial resistance. 2015. [cited 2020 Jun 1]. Available from: https://www.who.int/antimicrobial-resistance/global-action-plan/en/
- Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121.
- Gonzales R, Camargo CA Jr, MacKenzie T, et al. Antibiotic treatment of acute respiratory infections in acute care settings. Acad Emerg Med. 2006;13:288–294.
- Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.
- Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
- Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: an European Respiratory Society/American Thoracic Society (ERS/ATS) guideline. Eur Respir J. 2017;49:1600791.
- Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867–874.
- Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019;74:439–446.
- Sneh A, Pawan T, Randeep G, et al. Acute phase proteins as predictors of survival in patients with acute exacerbation of chronic obstructive pulmonary disease requiring mechanical ventilation. COPD. 2020;17:22–28.
- Miravitlles M, Monteagudo M, Solntseva I, et al. Blood eosinophil counts and their variability and risk of exacerbations in COPD: A population-based study. Arch Bronconeumol. 2020 Feb 12:pii: S0300-2896(19)30623–4. [ Epub ahead of print]. DOI:10.1016/j.arbres.2019.12.015
- Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73:422–430.
- Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18:95–107.
- Soler N, Esperatti M, Ewig S, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J. 2012;40:1344–1353.
- European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2018: European Centre for Disease Prevention and Control. 2019. [cited 2020 Jun 1]. Available from: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-europe
- Verbakel JY, Lee JJ, Goyder C, et al. Impact of point-of-care C reactive protein in ambulatory care: a systematic review and meta-analysis. BMJ Open. 2019;9:1–11.
- Butler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381:111–120.
- Alcázar Navarrete B, Ancochea Bermúdez J, García-Río F, et al. Patients with chronic obstructive pulmonary disease exacerbations: recommendations for diagnosis, treatment and care. Arch Bronconeumol. 2019;55:478–487.
- Llor C, Moragas A, Hernández S, et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:716–723.
- Miravitlles M, Moragas A, Hernández S, et al. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013;144:1571–1577.